Changes in Beneficial Ownership · 4
Maze Therapeutics, Inc.
MAZENASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-10022026_081010.xml
Filing details
- Report period
- 2026-10-01
- Issuer
- Maze Therapeutics, Inc.
- Issuer CIK
- 0001842295
- Trading symbol
- MAZE
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Coloma Jason V
- Reporting owner CIK
- 0001676170
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-01 | S · Form 4[F1] | 2,593 | D | 27.0241[F2] | 15,558 | I | The Coloma 2021 Irrevocable Trust[F3] |
| Common Stock | 2026-10-01 | S · Form 4[F1] | 31,908 | D | 27.0210[F4] | 191,447 | I | Coloma Family Trust[F5] |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Disposed
- I
- Indirect
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Common Stock | 27,362 | D |
Table key
- D
- Direct
Footnotes
- F1
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.↩ 1↩ 2
- F2
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.645 to $27.46 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4.↩ 1
- F3
- These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.↩ 1
- F4
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.585 to $27.47 per share, inclusive.↩ 1
- F5
- These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.↩ 1
Signature 1
- Signed
- /s/ Courtney Phillips, as attorney-in-fact
- Date
- 2026-10-02
Company context
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.